Janssen-Cilag International NV, a Johnson & Johnson company, announced the CHMP of the European Medicines Agency has recommended the approval of a Type II variation for DARZALEX, or daratumumab, subcutaneous formulation. The CHMP recommendation for daratumumab is supported by data from the Phase 3 PERSEUS study. Daratumumab is currently approved in eight indications for multiple myeloma.
The company said the positive CHMP opinion follows the recent FDA approval of daratumumab SC in combination with D-VRd for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for autologous stem-cell transplant.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.